ALTHOUGH the presence of proteases within malignant invasive tumours is well documented (Strauch, 1972; Wallach, 1975 ) the role of these enzymes in the phenotypic expression of malignant tumour cells has not been fully resolved (Wallach, 1975) .
There is evidence that proteases exert a mitogenic effect on cultured cells (Burger, 1970; Sefton and Rubin, 1970) and the activity of proteases at the cell surface has been implicated as one of the many factors regulating cell growth (Hynes, 1976;  Talmadge, Noonan and Burger, 1974) . The enhanced growth of virally transformed cells relative to their non-transformed homologues in vitro has been causally related to elevated protease activity of the transformed cells (Schnebli, 1974; Roblin, Chou and Black, 1975) and it has been suggested that tumour cell proteases not only potentiate the unrestrained growth of malignant tumour cells in vivo (Sylven, 1967; Bosmann and Hall, 1974) but also play an important role in tumour cell invasiveness (Strauch, 1972; Easty and Easty, 1976) .
A number of protease inhibitors, including synthetic reagents as well as naturally occurring substances such as aprotinin, exert growth inhibition of malignant transformed cells in vitro (Latner, Longstaff and Pradhan, 1973; Roblin et al., 1975) . Aprotinin (Trasylol ®) is a polyvalent inhibitor of the proteolytic enzymes trypsin, chymotrypsin, plasmin and the plasma kallikreins (Werle, 1970) . It has been claimed that aprotinin administered by various routes not only inhibits the growth and invasiveness of solid tumours in mice and hamsters, but also promotes lymphocyte infiltration and necrosis within the tumour tissue (Latner, Longstaff and Turner, 1974) . We have investigated whether aprotinin could exert an anti-tumour effect against a transplantable rat carcinosarcoma injected by different routes, and have examined the histopathology of tumours in aprotinin-and saline-treated rats and compared the degree of necrosis and host lymphoid cell infiltration in each case.
MATERIALS AND METHODS
Aprotinin was supplied as a solution (1.5 mg/ml, in 0-9o w/v aqueous NaCI) as Trasylol g, by Bayer Pharmaceuticals Ltd., Haywards Heath, Sussex, England. Due to its short half-life in serum (Werle, 1970) (Table II) . There was no difference in the character of the host cell infiltrate between groups, the prominence of host inflammatory cells (polymorphs, lymphocytes and macrophages) within the tumours being comparable in saline and aprotinin treatments.
The incidence of pulmonary tumour colonies in saline-and aprotinin-treated groups of rats is shown in Fig. 2 Strauch, 1972) and it has been postulated that elevated proteolytic activity may be causally related not only to loss of control of cell growth (Burger, 1973) but also decreased mutual adhesiveness, metastasis and invasiveness of malignant tumour cells (Easty and Easty, 1976) .
Second, there is a general association between neoplasia and fibinolysis, the fibrinolytic activity being responsible for dissolution of fibrinogen and fibrin within tumour tissue (Reich, 1973) . Malignant tumour cells initiate fibrinolysis by releasing serine protease(s) (" plasminogen activator(s) "), which convert plasminogen to the fibrinolytic protease plasmin (Davidson et al., 1969; Bjorlin, Pandolfi and Astedt, 1972; Reich, 1974) . In addition to its fibrinolysis, plasmin is also involved in the conversion of serum kininogens to vasoactive kinins (Back, 1966; Burrowes, Movat and Soltay, 1972) which may function in tumour growth through a pharmacological influence on the tumour vascular supply (Cater and Taylor, 1966; Back, 1966) .
Third, it has been suggested that proteases may impair the immune response of the tumour-bearing host by destruction of histocompatibility antigens on the tumour cell surface (Wallach, 1975) or by removal of specific receptors from antigen-reactive T lymphocytes (Latner, Longstaff and Turner, 1974) . In view of the role of proteases in malignant tumour growth outlined above it might be anticipated that administration of antiproteases to tumour-bearing 457 r. Several studies have failed to demonstrate tumour growth retardation in vivo with protease inhibitors (Peterson, 1968; Boeryd, 1965 Boeryd, , 1966 Hagmar, 1970) . In fact, enhanced tumour metastasis and growth have been observed following administration of the protease inhibitors tranexamic acid and e-aminocaproic acid (Peterson, 1968; Gillette, Findley and Conway, 1963) . However, in the latter studies the investigators considered it more likely that the observed tumour growth enhancement was attributable to an immunosuppressive effect of these reagents rather than their antiprotease function.
As a result of its binding to ubiquitous sialyl moities, aprotinin may be sequestered by many types of tissue cells (Kiernan and Stoddart, 1973; PughHumphreys and Thomson, in preparation) and therefore its potential effectiveness as an antitumour agent may well be limited by both its concentration and activity within the vicinity of the tumour, after its systemic administration. Continued infusion of aprotinin, which would ultimately lead to saturation of binding sites, might circumvent this limitation.
The increased incidence of experimental pulmonary metastases observed by Cliffton and Agostino (1964) in aprotinin-treated rats injected i.v. with Walker 256 carcinosarcoma cells may be explained by the known ability of aprotinin to inhibit fibrinolysis (Cliffton and Agostino, 1964; Amris, 1966) , since fibrin deposition promotes lodgement of Walker 256 cells within the pulmonary capillary network (Chew, Josephson and Wallace, 1976) . In terms of the number of lung tumour colonies produced in aprotinin-and salinetreated rats, we observed two effects of aprotinin on tumour growth, depending upon the relative timing of the injection of aprotinin and tumour cells. Injection of tumour cells, followed by immediate and then twice-daily injection of aprotinin, resulted in a significant decrease in the incidence of lung colony development, and these results contrast with those presented by Cliffton and Agostino (1964) . In the light of the potentiating effects of proteases on tumour cell growth (Hynes, 1976; Talmadge, Noonan and Burger, 1974) , our results can be rationalized in terms of an inhibition of tumourcell protease, culminating in impaired tumour cell growth. Only when aprotinin was first administered 3 days after i.v. inoculation of tumour cells did we observe an increase in the numbers of lung tumour colonies.
From our observations on the histopathology of both the solid intramuscular tumours and the lung tumour colonies, we have been unable to demonstrate a decrease in tumour invasiveness or an effect on the intensity and character of the host lymphoid cell infiltrate, in aprotinin-treated animals. In addition, we found no evidence that aprotinin administration enhanced tumour necrosis. These findings are in apparent conflict with those of Latner, Longstaff and Turner (1974) , who reported that the invasiveness and viability of a transplantable murine adenocarcinoma and a hamster fibrosarcoma were impaired by aprotinin, and who also found an increased host lymphoid infiltrate in tumours in aprotinin-treated tumourbearing hosts. In a more recent paper, Latner and Turner (1976) 
